Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | GHSR | Q92847 | 12/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | IDH2 | P48735 | 2/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.39 |
| ▸ | PRKDC | P78527 | 1/20 | 0.39 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4664054 | 0.91 | KDM4E (0.45) | KDM4EGHSRPIK3CDPIK3CAPIK3CB | |
| SCHEMBL2997886 | 0.89 | KDM4E (0.47) | KDM4EGHSRL3MBTL1IDH2 | |
| SCHEMBL13245995 | 0.88 | GHSR (0.47) | KDM4EGHSRIDH2 | |
| SCHEMBL4664052 | 0.85 | HTT (0.47) | GHSRPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL4664203 | 0.85 | GHSR (0.44) | KDM4EGHSRPKM | |
| SCHEMBL13245951 | 0.84 | ALDH1A1 (0.46) | KDM4EGHSRL3MBTL1 | |
| SCHEMBL2984221 | 0.82 | HTR6 (0.52) | KDM4EGHSRL3MBTL1PKM | |
| SCHEMBL4793678 | 0.80 | GHSR (0.46) | KDM4EGHSRPIK3CDPIK3CAPIK3CB | |
| SCHEMBL2984133 | 0.77 | GHSR (0.43) | KDM4EGHSRL3MBTL1PIK3CDPIK3CA | |
| SCHEMBL2989098 | 0.77 | GHSR (0.49) | GHSRL3MBTL1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100179168-A1 | ARYL AND HETEROARYL SULPHONAMIDES AS GROWTH HORMONE SECRETAGOGUE RECEPTOR AGONISTS | BLANEY EMMA LOUISE | 2010-07-15 | — | — | US | disclosed |
| US-20100179168-A1 | ARYL AND HETEROARYL SULPHONAMIDES AS GROWTH HORMONE SECRETAGOGUE RECEPTOR AGONISTS | BLANEY EMMA LOUISE | 2010-07-15 | — | — | US | disclosed |
| WO-2007118852-A1 | ARYL AND HETEROARYL SULPHONAMIDES AS GROWTH HORMONE SECRETAGOGUE RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179168-A1 | ARYL AND HETEROARYL SULPHONAMIDES AS GROWTH HORMONE SECRETAGOGUE RECEPTOR AGONISTS | GHSR, GHRHR, GIPR | KDM4E 3009/4885GHSR 1/4885L3MBTL1 4612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.